Pomalidomide 3rd Line Versus 4th Line For Rrmm
BLOOD(2017)
摘要
Background. Pomalidomide in association with dexamethasone is approved for RRMM in 3rd line and beyond based on the multicenter international phase 3MM-003 study that demonstrated greater efficacy for Pomalidomide plus dexamethasone over high dose dexamethasone. However, MM-003 mainly recruited RRMM with 5 prior lines +, and very few data are available regarding real life Pomalidomide-based treatment in 3rd and 4th line RRMM.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要